Foghorn Therapeutics to Cut 40% of Workforce After Drug Discontinuation

Foghorn Therapeutics will cut 40% of its workforce after discontinuing its experimental cancer drug, which was partnered with Eli Lilly. The drug failed to show sufficient benefit in an early-stage trial, and the companies will not extend their partnership.